-
 siRNA, overexpression, constitutive or inducible- In vitro & in vivo validation
- Phenotypic and functional assays
-
- 300 tumor cell lines
- Fresh primary tumor samples
- Cytotoxicity assays (MTS, SRB, BrDU)
- Clonogenicity assays
- FACS (apoptosis, cell cycle…)
- 51Cr release assay (ADCC, CDC)
|
-
 Preclinical formulation- MTD / MTTD (drug alone or combination)
- PK (HPLC-MS / MS, ICP-MS, ELISA, radiolabeled)
- Subcutaneous models
-
- Orthotopic & metastatic models
- Transgenic & chemoinduced models
- Xenografted Nude rats
- Optimization of administration schedule
- Combination with reference drugs
|
-
 Angiogenesis (functional histology & IHC)- Hypoxia quantification
- Immunological response characterization (cytokines, cellular populations’ activation…)
- Immune cells infiltration in tumors (IHC)
-
- µMRI (4.7T) under SPF conditions (morphology, Ktrans, BOLD, ADC, VSI…)
- µPET (FDG, FLT, FMISO…)
- Optimization of combination (pharmacological active dose, schedule, sequences, delays…)
-
- Nude rats
- Correlation between PD, PK, mechanistic effect, toxicity (hemato & neuro) and metabolism
- Use of classical techniques or imaging techniques
|
-
 Pierre Fumoleau, MD- 4 MDs, 5CRAs, 1 nurse
- 8 beds
- Clinical MRI and PET
|
Home
